Prevalence of these resistance mechanisms appear to be varied; deficiency in IFNγ signalling is uncommon, identified in only 4–10% of progressing tumours,20,21 while we have recently shown that defects in antigen production and presentation are more common, accounting for >70% of progressing tumours analysed.22 This evidence concerns the gene IFNG and neoplasm.